Soligenix Raises $7.5 Million in Public Offering

The latest announcement is out from Soligenix ( (SNGX) ).

On September 25, 2025, Soligenix entered a Securities Purchase Agreement for a public offering, raising approximately $7.5 million by selling common stock and warrants. The offering closed on September 29, 2025, and the proceeds will fund research, development, and commercialization activities, extending the company’s cash runway through the end of 2026. This financial move aims to support key inflection points and bolster Soligenix’s operational capabilities in the biopharmaceutical industry.

The most recent analyst rating on (SNGX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Soligenix stock, see the SNGX Stock Forecast page.

Spark’s Take on SNGX Stock

According to Spark, TipRanks’ AI Analyst, SNGX is a Underperform.

Soligenix’s overall stock score is primarily driven by its weak financial performance, characterized by declining revenues and persistent losses. While the technical analysis indicates some potential for short-term stability, the valuation and financial metrics suggest ongoing challenges. The company’s recent loan repayment is a positive step towards financial flexibility, but it does not alleviate the underlying financial and operational issues.

To see Spark’s full report on SNGX stock, click here.

More about Soligenix

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs. The company’s Specialized BioTherapeutics segment is advancing HyBryte™ for cutaneous T-cell lymphoma and expanding into psoriasis, while its Public Health Solutions segment develops vaccines for threats like ricin toxin, filoviruses, and COVID-19 using proprietary ThermoVax® technology.

Average Trading Volume: 11,374,018

Technical Sentiment Signal: Strong Sell

Current Market Cap: $5.14M

For detailed information about SNGX stock, go to TipRanks’ Stock Analysis page.